Category: Corporate News

Appoints Scotty Bowman as Managing Director

WALTHAM, Mass. – June 11, 2025 – Danforth Advisors LLC today announced the launch of Danforth Market Access & Value, a dedicated U.S. practice that deepens the firm’s ability to help life-science innovators secure timely, sustainable patient access to their therapies. In conjunction with the launch, veteran market-access executive Scotty Bowman has joined the company as Managing Director to lead the new division.

Danforth Market Access & Value delivers end-to-end market-access and payer consulting services—from patient-support programs and journey mapping to strategic payer engagement, pricing, reimbursement and launch planning—removing access barriers and aligning stakeholders so that breakthrough therapies reach patients faster and more efficiently.​​ The practice combines more than 40 years of collective pharmaceutical and biotech market-access expertise, including proven payer strategies, pricing excellence and successful product launches across multiple therapeutic categories.​​

“With capital constraints heightening the need for flawless market-access execution, launching Danforth Market Access & Value was a natural next step for us. Scotty’s track record of translating complex payer dynamics into clear paths to coverage makes him the ideal leader for this practice,” said Chris Connors, CEO of Danforth Advisors. “By integrating payer strategy alongside our existing finance, clinical-operations and communications offerings, we can now support clients from discovery through full commercial value realization.”

“I’ve long admired Danforth’s mission-critical role in helping emerging biotechs scale,” said Scotty Bowman. “I’m excited to build a best-in-class market access team that secures optimal coverage and reimbursement while reducing the operational burden on growing companies.”

Bowman brings more than two decades of experience in U.S. and global market access, most recently serving as President and Founder of Market Access GTN, LLC. He has led pricing, contracting and payer-strategy functions for multiple successful product launches and holds an MSJ from Seton Hall Law School. Additional team hires for Danforth Market Access & Value will be announced in the coming weeks.

About Danforth Advisors
Danforth is the life science industry’s trusted partner for strategic and operational support across business, clinical, and commercial functions. The company advises and executes in the areas of finance and accounting, strategic communications, human resources, risk management, clinical and regulatory, market research, and commercial readiness and launch. Founded in 2011, Danforth has partnered with more than 1,500 life science companies, private and public, across all stages of the corporate lifecycle. The company serves clients around the globe from its base in Waltham, Massachusetts and regional operations in New York, Pennsylvania, New Jersey, Maryland, California, and London. Additional information is available at www.danforthadvisors.com

Firms to Provide Integrated Services to Streamline Growth and Market Access

BASEL, Switzerland and WALTHAM, Mass. – February 20, 2025 – Ganda Business Solutions Ltd. and Danforth Advisors LLC today announced an exclusive partnership to support the business and clinical operations of Swiss biotech companies. Working jointly with localized expertise, the firms will provide integrated services to help Swiss companies scale with efficiency, expand to the US, and leverage flexible support in the areas of finance and accounting, human resources, investor relations, clinical operations, and regulatory strategy.

The combined team encompasses more than 400 consultants specializing in life science business operations, asset development support, and commercial readiness. The firms’ breadth of experience spans 500+ active clients and more than 60 IPO and reverse merger transactions.

“Our shared philosophy towards efficient capital allocation is reflected through our focus on providing variable and fractional support. We know that risk and uncertainty are inherent in biotech and organizational agility allows companies to remain flexible. This allows management to focus on the development activities knowing that strategic advice is on hand to help navigate the road ahead. For a majority of Swiss biotech companies, this road leads to the US, and by aligning with Danforth we can deliver both strategic guidance and well-managed operational execution,” said Christoph Rentsch, Managing Partner of Ganda Business Solutions.

The partnership also combines both teams’ deep relationships with investors, bankers, attorneys, CROs, and other pillars of the Swiss and US ecosystems, enabling them to seamlessly support clients as they scale their operations, advance clinical programs, and launch new products.

“Establishing a US nexus is often integral to Swiss biotechs’ strategy – whether through access to patients and payers via FDA approvals, financing from private and public investors, recruiting cohorts for clinical trials, or leveraging specialist capabilities from world leading physicians and experienced management teams. Our collaboration with Ganda gives Swiss clients assurance that they can navigate the US landscape with our well-developed strategies to de-risk execution as their operations advance,” said Michael Cunniffe, Managing Director of Danforth’s UK and European operations.

Having supported hundreds of biotech companies over two decades, Danforth and Ganda bring unmatched experience drawn from hands-on operational management and strategic advisory at executive and board levels.

“For a sustainable biotech growth story, the right talent and team composition play a key role, and must be aligned with the company’s vision and development goals. This talent is highly sought after and not always readily available,” said Catherine Ammann, Managing Partner of Ganda Business Solutions. “Through our partnership with Danforth, we can provide access to valuable skill sets where full time roles might be cost-prohibitive or difficult to fill.”

About Ganda Solutions
Ganda is a Professional Service Provider covering all General and Administration (G&A) tasks in the life science field. Ganda’s team of professionals has extensive industry experience at various leadership levels both in strategic and operational matters – within small and large organizations. Ganda operates from its Basel base and offers full support in English, German and French. Additional information is available at www.ganda-solutions.com.

About Danforth Advisors
Danforth is the life science industry’s trusted partner for strategic and operational support across business, clinical, and commercial functions. The company advises and executes in the areas of finance and accounting, strategic communications, human resources, risk management, clinical and regulatory, market research, and commercial readiness and launch. Founded in 2011, Danforth has partnered with more than 1,500 life science companies, private and public, across all stages of the corporate lifecycle. The company serves clients around the globe from its base in Waltham, Massachusetts and regional operations in New York, Pennsylvania, New Jersey, Maryland, California, and London.

Provides Global Market Research to Inform Strategy for Life Science Companies

WALTHAM, Mass.– December 17, 2024 – Danforth Advisors, LLC, today announced the acquisition of VPMR, LLC, a full-service, global market research firm serving life science and healthcare companies across all phases of the product lifecycle. Applying deep expertise in both traditional and technology-based research methods, VPMR provides vital insights to guide market opportunity assessment, new product development and strategic decision-making for clients.

The acquisition extends Danforth’s capabilities in the area of commercial readiness, delivering key data to shape launch strategy and marketing. Allison Fuller will continue to lead VPMR in her role as President.

“Given the high costs and stakes of drug development, market research is fundamental to optimizing chances of success. Whether to understand patient needs, market trends or the competitive landscape, VPMR brings the team and tools necessary to answer critical questions well ahead of investing in a particular path or program,” said Chris Connors, CEO of Danforth Advisors.

“We’re excited to join Danforth in helping life science companies streamline the path from novel science to successful commercial products that improve health and well-being for patients,” said Fuller. “We will continue to support new and existing clients with strategic, tactical and timely market information according to the highest standards in the healthcare and market research industry.”

VPMR specializes in the design and execution of custom research studies to address business questions arising from early clinical development through product maturity. The team comprises highly experienced research managers, analysts and moderators who conduct qualitative and quantitative research in wide-ranging therapeutic categories, synthesizing the findings to provide strategic direction to clients.

VPMR is the fifth organization to join Danforth, following the acquisitions of Advyzom and BW Health Group in 2024, Elite BioPharma Consulting in 2023 and Argot Partners in 2022. By aggregating specialists across the strategic and functional needs of life science companies under one roof, Danforth maximizes efficiency and applies the benefit of institutional knowledge, experience and connections across roles.

About VPMR
VPMR is a full-service, global custom primary market research firm serving the life science and healthcare industries. The company has been conducting research for nearly 20 years, formerly as Verispan’s Primary Market Research Division. Its customized market research solutions range from early clinical development through post-launch, incorporating qualitative and quantitative methods in an extensive range of therapeutic categories, respondent types, and treatment settings. Additional information is available at www.vpmrllc.com.

About Danforth Advisors
Danforth is the life science industry’s trusted partner for strategic and operational support across business, clinical, and commercial functions. The company advises and executes in the areas of finance and accounting, strategic communications, human resources, risk management, clinical and regulatory, and commercial readiness and launch. Founded in 2011, Danforth has partnered with more than 1,000 life science companies, private and public, across all stages of the corporate lifecycle. The company serves clients around the globe from its base in Waltham, Massachusetts and regional operations in New York, Pennsylvania, New Jersey, Maryland, California, and London.

Establishes Complete Range of Clinical and Regulatory Services for Life Science Companies

WALTHAM, Mass.– September 10, 2024 – Danforth Advisors, LLC, today announced the acquisition of Advyzom, LLC, a leading regulatory affairs consultancy, creating a single, comprehensive resource for life science companies to access the expertise required on the path to proof-of-concept, regulatory approval, and market entry.

Danforth’s clinical and regulatory bench now spans experts across preclinical and medical advisory, clinical development operations, regulatory strategy, FDA liaisons and submissions, medical writing, and clinical and CMC outsourcing. By assembling the critical functions of asset development under one roof, Danforth maximizes operational efficiency for life science companies and applies the benefit of deep institutional knowledge across key roles.  

Founded in 2011, Advyzom comprises approximately 30 specialists with backgrounds in biotechnology and big pharma, providing expertise in global regulatory strategy, FDA relationships as US agents, document publishing,  regulatory submissions, and medical writing. The team serves as a primary interface to health authorities and has led or supported the achievement of hundreds of regulatory milestones for clients, including INDs, NDA/BLA filings and approvals, and numerous FDA designations to expedite development and approval. Founder and CEO Cindy Dinella will continue in her leadership role.

“Advyzom brings top talent and an exceptional track record in regulatory strategy, timely execution, and positive working relationships with health authorities – all critical to achieving clients’ drug development and commercialization objectives. We now have a fully integrated suite of clinical and regulatory services that can adapt to every stage of development,” said Chris Connors, CEO of Danforth Advisors. “More broadly, this latest acquisition advances our vision to be an agile foundation for life science companies – providing the variable teams and skill sets they need to run the business, develop assets, and launch products.”

“We are privileged to work with pioneering innovators to help much-needed treatments reach patients, and in Danforth we found a team that shares our passion for this cause,” said Dr. Dinella. “We are excited for the opportunity to partner with more life science companies who require thoughtful leaders and hands-on collaborators to navigate the regulatory landscape across the development journey.”

Advyzom is the fourth organization to join Danforth, following the acquisitions of BW Health Group in 2024, Elite BioPharma Consulting in 2023, and Argot Partners in 2022. In December 2021, Danforth announced an investment by Avesi Partners, LLC, to accelerate plans to meet an ever-broadening scope of strategic and operational needs for life science companies.

About Advyzom

Advyzom is a leading boutique consulting company specializing in highly strategic regulatory and development advice and services for clients in the pharmaceutical and healthcare industries. The company is headquartered in New Jersey and supports the development programs of clients at all stages as a virtual or embedded extension of their teams. Additional information is available at www.advyzom.com.

About Danforth Advisors

Danforth is the life science industry’s trusted partner for strategic and operational support across corporate, clinical, and commercial functions. The company advises and executes in the areas of finance and accounting, strategic communications, human resources, risk management, clinical and regulatory, and commercial readiness and launch. Founded in 2011, Danforth has partnered with more than 1,000 life science companies, private and public, across all stages of the corporate lifecycle. The company serves clients around the globe from its base in Waltham, Massachusetts and regional operations in New York, Pennsylvania, Maryland, California, and London.

Adds Commercial Readiness and Launch to Range of Integrated Services for Life Science Companies

WALTHAM, Mass.– May 29, 2024 – Danforth Advisors, LLC, today announced the acquisition of BW Health Group, a leading provider of commercial readiness and product launch services for small and mid-sized life science companies. The addition of BW gives Danforth an unrivaled capability to serve the strategic and operational needs of life science companies to run their business, develop products and successfully bring them to market. These services include advisory and execution in finance and accounting, strategic communications, human resources, enterprise risk management, clinical operations, regulatory affairs and now commercialization.

“Since inception, we have strategically curated the talent, skill sets, services and connections required to be the flexible infrastructure partner to life science companies. We expertly manage business and clinical functions for clients large and small, adapting and scaling as their needs evolve,” said Chris Connors, Chief Executive Officer of Danforth. “With BW Health Group, we are now integrating specialists in commercial planning, product launch and on-going marketing – helping treatments reach patients and stay competitive in the marketplace. We’re thrilled to welcome BW and play a role in this critically important phase of the journey for clients.”

“BW Health Group prides itself on cultivating market-leading brands particularly for small to mid-sized life science companies, and our success derives from our senior-level attention to clients, expertise in product commercialization and significant investments in talent and technology to enable data-driven insights into the marketplace and patient communities,” said Thad Bench, Founder of BW Health Group. “Danforth has built a unique offering by aggregating life science specialists across multiple disciplines, and BW Health Group provides a natural extension to support clients in the critical commercial readiness, product launch and post-launch phases. We look forward to working closely with our Danforth colleagues to bring these services to clients.”  

Tom McDonnell will lead BW Health Group in the role of Chief Executive Officer going forward, and Thad Bench will contribute in an advisory role.  

BW Health Group comprises the following entities:

• Benchworks, a full-service communications agency that offers pre-product launch, launch and post-launch capabilities including creative services, strategic planning, data analytics, digital and print advertising planning and placement. The firm serves as agency of record (AOR) for top pharmaceutical brands, with expertise in cell and gene therapy and rare disease, among other therapeutic areas. The firm’s talent includes former industry executives and brand leaders, creative agency professionals and technology experts focused on building strong pharmaceutical brands.
• BW Consulting, an outcomes-focused life science commercialization strategy consultancy that provides commercial strategy, launch planning and gap analysis, product lifecycle management and payor strategy services. With vast experience in gene therapy and rare disease, advanced therapies and emerging biologics, the firm has a demonstrated track record of leading successful products and brands through all stages of product launch, including launch preparation and post-launch lifecycle management.

BW Health Group is the third organization to join Danforth, following the acquisitions of Argot Partners in 2022 and Elite BioPharma Consulting in 2023. In December 2021, Danforth announced an investment by Avesi Partners, LLC, to accelerate plans to meet an ever-broadening scope of strategic and operational needs for life science companies.

Connors added: “With both BW Health Group and Argot Partners operating as part of Danforth, we can meet a full spectrum of strategic communications, marketing and creative needs for clients to effectively reach a wide range of audiences. We have grown our business both organically and through strategic acquisition, and we will continue on that path to meet the needs of life science companies at all stages of evolution.”

Learn more about the Danforth companies here: https://bwhealthgroup.com/danforthcompanies/

About BW Health Group

BW Health Group is a full-service commercialization platform focused on cultivating market-leading brands for life science companies. The company comprises two integrated portfolio companies: BW Consulting, a biopharmaceutical management consultancy specializing in product launch, with expertise in cell and gene therapy, and Benchworks, a full-service biopharmaceutical creative agency focused on delivering experiences that optimize brand engagement. BW Health Group was established in January 2019 and builds upon a two-decade legacy of experience in pharmaceutical marketing. The firm is led by industry brand executives and strategists whose goal is to help clients and their brands navigate an ever-evolving healthcare system. For more information, visit www.bwhealthgroup.com.

About Danforth Advisors

Danforth exclusively supports the core business and clinical functions of life science companies. The company provides strategic advisory and operational execution in the areas of finance and accounting, clinical and regulatory, strategic communications, commercial readiness and launch, human resources and risk management. Founded in 2011, Danforth has been a trusted partner to more than 1,000 life science companies, private and public, across all stages of the corporate lifecycle. The company serves clients around the globe from its base in Waltham, Massachusetts and regional operations in New York, Pennsylvania, Maryland, California and London. Additional information is available at www.danforthadvisors.com. 

WALTHAM, Mass.– November 2, 2023 –Danforth Advisors, LLC, today announced newly-established operations in the United Kingdom (UK) to support local life science companies with strategic advisory and management of corporate and clinical functions – scaling from initial company start-up through all phases of growth. The company’s integrated, stage-adjusted resources range from financing strategy, operational finance and accounting, human resources and strategic communications to operational and regulatory support for preclinical and clinical development.

Initially based in London, Danforth’s regional presence will extend to Cambridge and Oxford; covering the preeminent life sciences ecosystem known as the “golden triangle;” in addition to Northern England, Scotland and Bristol; where universities are increasingly fueling new company formation. Danforth’s UK operations will be led by Michael Cunniffe, Managing Director, who brings more than 20 years of experience to the role.

“This is a very exciting step in expanding our international reach, recognizing the number of companies emerging from world-class universities and research institutions in the UK and our ability to support their journey,” said Chris Connors, CEO of Danforth Advisors. “Particularly in today’s market, capital efficiency is critical, and we can help companies minimize fixed costs without compromising the integrity of their science or business operations – keeping their progress on track. We are thrilled to welcome Michael to lead our UK team and service to clients in the region.”

“I have long admired the unique role Danforth plays in helping life science companies scale and operate at their best. It’s a privilege to lead the company’s first overseas expansion,” said Cunniffe. “The UK has a proud history of pioneering novel medicines, and despite the challenging capital markets, we’ve seen many therapies advance and new companies established around novel technologies. I look forward to expanding Danforth’s UK team to serve a greater number of these companies, whether assisting with capital raising, managing day-to-day operations or de-risking expansion to the United States.”

Cunniffe is an accomplished life science CFO with experience in both the UK and US markets and across all stages of development, from discovery through commercialization. He has led numerous IPO and financing transactions and built and scaled infrastructure to enable commercial success. He holds a Masters in Finance degree from London Business School.

About Danforth Advisors

Danforth is the life science industry’s trusted partner for enterprise-wide managed functions, from corporate to clinical. The company’s variable, integrated capabilities include C-Level Advisory, Finance & Accounting, Human Resources, Strategic Communications, Risk Management, and Development Strategy & Operations. Founded in 2011, Danforth has been a strategic and operational partner to more than 1,000 life science companies, private and public, across all stages of the corporate life cycle. The company serves clients around the globe from its headquarters in Waltham, Massachusetts and regional bases in New York, Pennsylvania, California, and London. Additional information is available at www.danforthadvisors.com. 

Danforth Advisors Extends Variable Resource Model to Preclinical and Clinical Development; Acquires Elite BioPharma Consulting to Add Clinical Development Operations to Range of Capabilities

WALTHAM, Mass.– September 6, 2023 – Danforth Advisors, LLC, today announced the acquisition of Elite BioPharma Consulting, Inc., broadening the range of its newly formed Development Strategy and Operations (DS&O) practice and supporting life science companies in the advancement of preclinical and clinical programs without the burden of fixed costs. With the acquisition of Elite, Danforth becomes the single provider of enterprise-wide managed functions – from corporate to clinical – tailored to support life science companies at all stages of development.   

The Elite acquisition adds the following capabilities to Danforth’s DS&O practice.

• Clinical Development Operations
• Clinical Project & Trial Management
• Clinical Monitoring
• Program Management
• Regulatory Affairs
• Medical Writing

Founders Jill C. Bossi, Shawna H. Evans, and Connacht M. Peterson will continue to lead the Elite team.

“Our vision from inception was to become a variable resource exclusively for life science companies, aggregating cross-functional specialists as an alternative to over-building internal resources – a diversion of capital away from the science,” said Gregg Beloff, Co-Founder and Managing Director of Danforth. “Our model has proven effective on the general & administrative side for hundreds of life science companies – many of whom we supported from early stages through IPO or acquisition and beyond. With our expansion into DS&O and the acquisition of Elite, we have taken our biggest step yet towards making our full vision a reality.”

“The Elite team applies deeply rooted expertise and leadership skills to drive clinical development programs forward. We offer comprehensive consulting services through every stage of product development,” said Shawna Evans, Founder and Co-President of Elite. “Danforth is a natural fit for our team and positions us within a large ecosystem of strategically integrated services dedicated to bringing novel therapies and devices to market.”

“To launch and advance life science organizations through preclinical and clinical stages requires meticulous planning and decision-making at each step, with expertise across multiple disciplines. Our DS&O practice, including the Elite team, has been shaped by decades of industry experience and built with the highest caliber of talent across the development continuum, from preclinical planning and strategy to oversight of clinical trial design and execution,” said Ramani Varanasi, recently appointed Managing Director of Danforth’s DS&O practice. “We will continue to grow this practice area to fulfill the many needs of companies developing products to improve human health and well-being.”

Danforth partners with life science companies to help them launch, grow, transition and optimize their business operations at all stages of development and in geographies across the globe. The company acquired Argot Partners, LLC, a leading strategic communications consultancy focused exclusively on the life sciences industry, in January 2023, adding a full scope of investor relations and corporate communications services to help clients articulate their science and its value to key stakeholders. In December 2021, Danforth announced an investment by Avesi Partners, LLC, to accelerate plans to meet an ever-broadening scope of strategic and operational needs for emerging life science companies.

About Elite BioPharma Consulting

Elite collaborates with pharmaceutical, biotechnology and medical device companies to support their product development process from initial application through final regulatory filing. The firm’s founders and consultants deliver broad experience in all areas of clinical research, drug and device development, as well as deep knowledge required to successfully execute both early and late phase clinical development programs. The firm was founded in 2019 and is headquartered in Boston, Massachusetts. For more information, visit www.elitebpconsulting.com.

About Danforth Advisors

Danforth is the life science industry’s trusted partner for enterprise-wide managed functions, from corporate to clinical. The company’s variable, integrated capabilities include C-Level Advisory, Finance & Accounting, Human Resources, Strategic Communications, Risk Management, and Development Strategy & Operations. Founded in 2011, Danforth has been a strategic and operational partner to more than 1,000 life science companies, private and public, across all stages of the corporate life cycle. The company serves clients around the globe from its headquarters in Waltham, Massachusetts and regional bases in New York, Pennsylvania, California, and London. Additional information is available at www.danforthadvisors.com. 

Adds Strategic Communications to Range of Integrated Services, Advancing Company’s Position as the Single-Source Business Partner to Life Science Innovators

WALTHAM, Mass. and NEW YORK – January 4, 2023 – Danforth Advisors, LLC, today announced the acquisition of Argot Partners, LLC, a leading strategic communications consultancy focused exclusively on the life sciences industry. With the acquisition, Danforth now provides a full scope of investor relations and corporate communications services to help clients articulate their science and its value to key stakeholders. Founders Andrea F. Rabney and David M. F. Pitts will continue to lead Argot.

“While life science companies commonly outsource general and administrative functions for capital efficiency, they face the subsequent challenge of managing disparate providers who work in functional silos – often without coordination or specialized expertise in life sciences,” said Gregg Beloff, Co-Founder and Managing Director of Danforth. “Danforth is the first to aggregate cross-functional specialists and services exclusively for life science companies, applying deep sector expertise, institutional knowledge and connections to support clients across the entire corporate life cycle.”

The Argot acquisition adds valuable, complementary services to Danforth’s capabilities, which now include the following:

• C-Level Advisory: including thought partnership, financing strategy, corporate development and stakeholder relations for companies ranging from start-up through public and commercial stages;
• Finance & Accounting: including operational and technical accounting, and financial planning and analysis, for companies ranging from start-ups to more mature organizations who require services such as the execution of IPO, SPAC and reverse merger transactions;
• Human Resources: including organizational design and development, workplace policies and procedures, talent acquisition, people operations and internal communications;
• Clinical Business Operations: including clinical outsourcing strategy, contract structure and negotiation, clinical finance management and CMC/supply chain advisory;
• Risk Management: including risk assessment, mitigation plans, insurance assessment and procurement; and
• Strategic Communications: including corporate communications, investor relations, public relations and creative services.

Beloff added: “We’re thrilled to welcome Argot and to extend their talented team to our clients, who require thoughtful strategy and programs to communicate the story of their science, progress and potential. Science drives value in our industry, and we believe that companies can leverage our scalable, integrated corporate and clinical support services to maximize the amount they invest in their science. We aspire to be this industry’s go-to partner for expertly and efficiently managed business functions – now including strategic communications.”

“Argot strives to provide the highest-level counsel and execution on a full suite of corporate communications services, including investor relations, merged media, creative services and event planning,” said Andrea F. Rabney, Founder and Chief Executive Officer of Argot.  “We aligned quickly with Danforth on their vision for unlocking value for life science companies, and how being a part of their ecosystem could help streamline and accelerate the delivery of innovation. Our team has the great privilege of working in an industry that brings benefit to public health, and we look forward to working together with the Danforth team to deliver on this vision.”

Argot serves clients of all sizes and stages of development, from early preclinical to mature commercial, in a number of areas within the life sciences, including therapeutics, bio-economy, tools and diagnostics, and med-tech. The firm’s disciplines include corporate communications and investor relations; public relations and digital media; IPO, data, partnership, product approval, commercial launch, M&A, and special situations communications; executive visibility and training; ESG communications; event planning; and a full suite of creative services. Argot has also developed an exclusively life-sciences focused relationship management platform, Argot Acumen, that enables relationship tracking for its clients with investors, analysts, bankers and media.

“Danforth has evolved well beyond our origins in CFO advisory, and, with Argot, we’ve taken another major step towards our long-range vision of being the single-source business partner to life science innovators at all stages of development and commercialization,” said Chris Connors, Chief Executive Officer of Danforth. “We speak with life science CEOs every day, both new and seasoned, who are seeking a reliable partner to fill strategic and operational gaps that otherwise divert attention away from their core focus – the science. This is the very purpose of Danforth – to form the scalable business operation that allows life science companies to build value, grow and deliver important innovation to patients.”

Danforth has partnered with more than 1,000 life science companies to help them launch, grow, transition and optimize their business operations at all stages of development and in geographies across the globe. In December 2021, the company announced an investment by Avesi Partners, LLC, to accelerate plans to meet an ever-broadening scope of strategic and operational needs for emerging life science companies.

About Argot Partners

Argot Partners is a strategic communications consultancy exclusively focused on the life sciences that provides a broad suite of services to over 90 clients across all stages of their corporate evolution. The firm’s disciplines include corporate communications and investor relations; public relations and digital media; IPO, data, partnership, product approval, commercial launch, M&A, and special situations communications; executive visibility and training; ESG communications; event planning; and a full suite of creative services. Argot Partners was founded in 2007, is headquartered in New York, with offices in the Boston area. For more information, visit www.argotpartners.com.

About Danforth Advisors

Danforth Advisors is the life science industry’s leading provider of outsourced corporate and clinical business functions. Danforth’s services span wide-ranging needs, whether short or long term, including C-level advisory, finance & accounting, human resources, clinical business operations, risk management and strategic communications. Founded in 2011, Danforth has been a trusted thought partner to more than 1,000 life science companies, private and public, across all stages of the corporate life cycle. The company serves clients nationwide and overseas from its headquarters in Waltham, Massachusetts and regional bases in New York, Pennsylvania and California. Danforth was recognized among the Top Workplaces USA 2022 and among The Boston Globe’s Top Places to Work in Massachusetts in 2021.

Stamford, CT, December 16, 2021 – Avesi Partners, LLC (“Avesi”) announced they have made an investment in Danforth Advisors, LLC (“Danforth”), the life science industry’s leading resource for strategic advisory and flexible, scalable management of corporate and clinical business functions. This investment will accelerate Danforth’s plans to meet the additional needs of emerging life science companies – who, apart from sound science, require sector-specific expertise to start, grow and successfully operate towards their best possible outcomes.

Danforth’s leadership and consulting teams have extensive experience in the life sciences industry, ranging from initial company start-up, operational accounting and financing strategy to clinical contracting and human resources. With record levels of capital invested in life sciences over the past two years, more new companies are seeking operational guidance and support that can scale as their needs evolve from preclinical through commercial stages. Accordingly, Danforth is expanding its service offerings and geographic footprint to fill these pressing gaps.

Click here to read the full press release.